IP Library Granted Patent US 11,364,270
Granted Patent B2
US 11,364,270 · App. 17/411,983 · Granted Jun 21, 2022

Methods and compositions relating to microbial treatment and diagnosis of disorders

Inventors: Colleen Cutcliffe (Menlo Park, CA); John S. Eid (San Francisco, CA); James H. Bullard (San Francisco, CA); Marcus F. Schicklberger (Richmond, CA)
Assignee: Pendulum Therapeutics, Inc.
A61K35/745A23L33/135A61K9/0053A61K9/2846A61K9/48A61K9/4816A61K9/4891A61K31/00A61K31/733A61K35/74A61K35/741A61K35/742A61K45/06C12N1/20C12Q1/689G01N33/66A23V2002/00A61K2035/115G01N2333/605G01N2800/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,364,270
App. No.
17/411,983
Granted
Jun 21, 2022
Kind
B2
Abstract

The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.

Claims (27)

1. A method of producing a microbial composition suitable for human consumption, the method comprising:

culturing Akkermansia muciniphila in a culture medium comprising substantially a plant-based culture medium, thereby generating cultured Akkermansia muciniphila ; and

formulating the cultured Akkermansia muciniphila into a unit dosage form thereby producing the microbial composition suitable for human consumption.

2. The method of claim 1 , wherein the unit dosage form comprises the cultured Akkermansia muciniphila in a powdered form.

3. The method of claim 1 , wherein the unit dosage form comprises the cultured Akkermansia muciniphila in a lyophilized form.

4. The method of claim 3 , wherein the culturing of the Akkermansia muciniphila is carried out anaerobically.

5. The method of claim 1 , wherein the unit dosage form is a capsule.

6. The method of claim 1 , wherein the unit dosage form is a food composition in a form of a bar.

7. The method of claim 1 , wherein the unit dosage form further comprises the plant-based culture medium.

8. The method of claim 7 , wherein the unit dosage form comprises the plant-based culture medium in a powdered form.

9. The method of claim 1 , wherein the unit dosage form comprises at least 1×10 5 CFUs of the cultured Akkermansia muciniphila.

10. The method of claim 1 , wherein the unit dosage form further comprises one or more of: Eubacterium hallii, Clostridium beijerinckii, Clostridium butyricum, Clostridium indolis, Bifidobacterium infantis , or Faecalibacterium prausnitzii.

11. The method of claim 1 , wherein the unit dosage form does not contain dairy.

12. The method of claim 1 , wherein the plant-based culture medium comprises an amino acid source that is a plant-protein hydrolysate.

13. The method of claim 1 , wherein the unit dosage form further comprises a prebiotic.

14. The method of claim 1 , wherein the culture medium further comprises one or more vitamins, one or more salts, a buffer, or a combination thereof.

15. The method of claim 1 , wherein the culture medium consists essentially of the plant-based culture medium.

16. The method of claim 1 , wherein the culture medium consists of the plant-based culture medium, one or more salts, one or more vitamins, and a buffer.

17. A method of generating cultured Akkermansia muciniphila , the method comprising:

culturing Akkermansia muciniphila in a culture medium comprising substantially a plant-based culture medium, thereby generating the cultured Akkermansia muciniphila.

18. The method of claim 17 , further comprising processing the cultured Akkermansia muciniphila into a powdered form.

19. The method of claim 17 , further comprising processing the cultured Akkermansia muciniphila into a lyophilized form.

20. The method of claim 19 , wherein the culturing of the Akkermansia muciniphila is carried out anaerobically.

21. The method of claim 17 , wherein the plant-based culture medium comprises an amino acid source that is a plant-protein hydrolysate.

22. The method of claim 17 , wherein the culture medium further comprises one or more vitamins, one or more salts, a buffer, or a combination thereof.

23. The method of claim 17 , wherein the culture medium consists essentially of the plant-based culture medium.

24. The method of claim 17 , wherein the culture medium consists of the plant-based culture medium, one or more salts, one or more vitamins, and a buffer.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2022
From: CUTCLIFFE, COLLEEN; EID, JOHN S.; BULLARD, JAMES H.; SCHICKLBERGER, MARCUS F.
To: WHOLE BIOME INC.
Reel/Frame 060147/0730 →
CHANGE OF NAME Recorded Jun 9, 2022
From: WHOLE BIOME INC.
To: PENDULUM THERAPEUTICS, INC.
Reel/Frame 060317/0118 →
SECURITY INTEREST Recorded Jan 18, 2022
From: PENDULUM THERAPEUTICS, INC.
To: TRINITY CAPITAL INC.
Reel/Frame 058678/0276 →